AcuityMD, the AI platform for MedTech, today introduced advanced market analysis in AcuityAI, powered by a new research agent that delivers company, brand, and product-level market share, pricing comparisons, and patient pathway analyses to calculate total addressable market size in minutes. MedTech leaders gain fast, accurate market analysis – a traditionally time-consuming process – to improve long-term decision-making.

MedTech market analysis typically requires piecing together information across claims data, syndicated reports, clinical research, internal data, and more, which customers say takes weeks or even months. And while general-purpose AI has made research faster, it lacks the right data and industry context required for high-stakes decisions. AcuityMD’s research agent closes that gap. It is grounded in the company’s proprietary MedTech ontology that connects physicians, facilities, networks, procedures, and reimbursement. The agent runs multi-step analyses scoped to a company’s market, cited at every step, and re-runnable as new data arrives, giving leaders a defensible starting point for planning, investment, and mergers and acquisitions.

“AcuityAI brings objective data into our diligence process, proving particularly valuable in our understanding of markets and how they’re evolving over time,” said Chris Murray, Principal at MVM Partners, an investment company with a global outlook spanning medical technology, pharmaceuticals, diagnostics, contract research and manufacturing, digital health, and other sectors of healthcare.

AcuityMD’s new agent, which can be enabled for select users, allows MedTech leaders to answer questions such as the following:

  • Competitive strategy: Where are we gaining or losing share against competitors, and how does our pricing compare?
  • Upstream marketing and product management: How large is the market for a new indication, how do patients move through care today, and which segments warrant closer investigation?
  • M&A and corporate strategy: What does the market data indicate about a potential acquisition target?

“MedTech teams now have a faster path from a market question to a decision, directly within AcuityAI,” said Brian Collins, AcuityMD Chief Product Officer. “Our research agent brings together deep MedTech context and real-world industry data and activity, not directional estimates from syndicated reports, general-purpose datasets, or vague, forward-looking opinion surveys. Research that used to take weeks or even months can now be completed in minutes.”

AcuityMD is demonstrating the research agent at its annual Flywheel 2026 conference (October 13-14) in Philadelphia and at booth #1102 at The MedTech Conference (October 18-21) in Boston, where AcuityMD and Vericel will speak about AI in MedTech.

About AcuityMD
AcuityMD is the AI platform for MedTech trusted by over 500 MedTech companies – including 16 of the top 20. Commercial leaders use AcuityMD to identify target markets, surface top opportunities, and grow their business. By combining real-world healthcare data with AI-powered insights, AcuityMD enables companies from pre-commercial to enterprise to understand where and how to sell faster to accelerate the adoption of medical technology. AcuityMD ranked No. 316 on the 2026 Inc. 5000 list of the fastest-growing private companies in America and was named to Forbes’ 2025 “Next Billion-Dollar Startups” list – an elite group of 25 venture-backed U.S. companies identified as most likely to reach a $1 billion valuation.

Media gallery

About The Author
Business Wire